Evotec SE

Chief Executive Officer

Dr Christian Wojczewski (born in 1971, German citizen) joined Evotec as Chief Executive Officer and Chairman of the Management Board on 01 July 2024. Dr Wojczewski has over 20 years of experience in various top management positions, most recently at Mediq and Linde Healthcare. He is an experienced CEO with a proven track record in building and leading large, high-performing life science organisations, and with deep strategic, operational and transformational expertise. Dr Wojczewski holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe-University in Frankfurt am Main. He worked as a manager at McKinsey for companies in the life science and chemical industries in Europe and the USA. In 2005, he joined Linde, the global market leader for medical and industrial gases. After various roles within the company, Dr Wojczewski took over as Head of Group Strategy and later additionally assumed leadership of Linde Healthcare, one of the Group’s key growth businesses. During his tenure, Linde Healthcare developed into the global market leader for medical gases and services for patients with chronic respiratory diseases operating in more than 60 countries. In 2017, Dr Wojczewski joined Mediq in the Netherlands, a European leader in medical devices and related services, as group CEO. Under Dr Wojczewski’s leadership, Mediq achieved an impressive turnaround with strong EBITDA recovery and towards profitable growth.

Latest update: July 2024

Chief Financial Officer

Laetitia Rouxel (born in 1973, French citizen) joined Evotec as Chief Financial Officer and Member of the Management Board on 01 April 2023. Rouxel has more than 25 years of finance experience in various sectors such as Life Sciences, Food, Cosmetics and Building industry. A graduate of the French Business school ISG, she started her career with finance and commercial roles in the Pharma industry at Pfizer and J&J. She went on to work for the French multinational food-products corporation Danone, where she covered various leading Finance positions in multiple regions for R&D, Medical and Baby Nutrition based in France and in the Netherlands. She then joined the beauty company Coty in Switzerland, where she became divisional CFO. Before joining Evotec, she was Global CFO of Wavin, a solutions leader for the building and infrastructure industry.

Lastest update: April 2024

Chief Scientific Officer

Dr Cord Dohrmann (born in 1964, German citizen) joined Evotec as Chief Scientific Officer and Member of the Management Board in 2010. Dr Dohrmann has spent over 25 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr Dohrmann completed his MA thesis at the Max Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining a Max Planck Institute spin-off company, DeveloGen, in 1999. During his ten-year tenure, he served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr Cord Dohrmann is a member of the Supervisory Boards of Eternygen and Breakpoint Therapeutics, a Non-Executive Member of the Board of Directors of Facio Therapies and a Board Observer of Immunitas Inc. He has been advising the European Commission, the Max Planck Institute as well as various venture capital firms. In February 2021, Dr Dohrmann was appointed to the German Council of Science and Humanities.

Latest update: April 2024

Chief Operating Officer & Site Head Toulouse

Dr Craig Johnstone (born in 1970, British citizen) was appointed Chief Operating Officer and Member of the Management Board of Evotec on 01 January 2019. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency. From April 2015, Dr Johnstone was Directeur General and Site Head, Evotec (France) SAS, and from January 2017, he was appointed Global Head, Integrated Drug Discovery. Dr Johnstone is a successful drug discovery leader with over 20 years’ experience particularly in the areas of diabetes, inflammation and oncology. Between 1994 and 2012, Dr Johnstone served in a number of project, function, matrix and leadership roles at AstraZeneca, Prosidion and Rapier Research where he led teams and groups, which discovered numerous candidate drugs for clinical development including AZD1656, which reached PhIIb for Type II Diabetes. During this time, Dr Johnstone also developed expertise in LEAN-inspired process excellence in drug discovery and developed a keen interest in the interface between creativity, innovation and process improvement to deliver the highest performance drug discovery, advising teams and implementing multi-site, international change initiatives to drive performance. Dr Johnstone is a Fellow of the Royal Society of Chemistry and Chartered Chemist (FRSC CChem) and holds BSc in Chemistry and a PhD in organic and organometallic synthesis and is an accredited LEAN Sigma Black Belt. He has published more than 70 patents and papers in drug discovery, medicinal and synthetic chemistry, innovation and LEAN methods applied to the inventive processes of drug discovery. Dr Johnstone does not hold any memberships in supervisory bodies.

Latest update: April 2024

Chief People Officer

Aurélie Dalbiez (born in 1977, French citizen) joined Evotec as Chief People Officer and Member of the Management Board on 15 June 2024. In her role as CPO, Aurélie oversees the development and implementation of Evotec’s people strategy, focusing on fostering a culture of innovation, collaboration, and belonging. With over 25 years of international people leadership experience, Aurélie has a wealth of experience and expertise in Human Resources and a proven track record of driving organizational transformation and fostering employee engagement.

Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer (“CHRO”) at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands. Previously, she was Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career in the banking industry, first at Deutsche Bank and later at Capital Group.

Aurélie brings a multi-cultural background and perspective. She lived in the United States, earned her university degree in International Business in Lyon, France and worked internationally throughout her career, mainly in Switzerland and The Netherlands with assignments in Spain, Germany, and France. She is fluent in French and English and also speaks German and Spanish.

Latest update: June 2024